Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

AJMC
Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com
C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Top 5 AJMC® Articles of September 2018
September 30th 2018

Top 5 AJMC® Articles of September 2018

Here are the top 5 articles for the month of September.
Working Toward CAR T-Cell Treatments With Fewer Side Effects
September 30th 2018

Working Toward CAR T-Cell Treatments With Fewer Side Effects

Mary Caffrey
Loyola University Chicago and Loyola Medicine announced plans this week to develop their own chimeric antigen receptor T-cells that would have less toxic side effects.
Lack of Discussion Around Cancer Treatment Costs Leads to Financial Toxicity
September 29th 2018

Lack of Discussion Around Cancer Treatment Costs Leads to Financial Toxicity

Samantha DiGrande
Earlier this week, 3 studies were released that investigated the financial difficulties seen in patients living with cancer. Such difficulties are referred to as “financial toxicity,” which was studied in patients with metastatic breast cancer and older patients, as well as the conversations about cost of care that women with breast cancer have with their physicians.
Imfinzi Plus Chemotherapy Reduced Risk of Death by One-Third in Stage III NSCLC
September 28th 2018

Imfinzi Plus Chemotherapy Reduced Risk of Death by One-Third in Stage III NSCLC

Samantha DiGrande
Earlier this week, drug manufacturer Astrazeneca announced the results from a phase 3 trial studying durvalumab (Imfinzi) among patients with stage III unresectable non­–small cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy.
The Risk of Creating Healthcare Monopolies
September 26th 2018

The Risk of Creating Healthcare Monopolies

Burnout and Resilience Among Oncologists
September 26th 2018

Burnout and Resilience Among Oncologists

Healthcare Payment Models
September 26th 2018

Healthcare Payment Models

Oncology Care Within Integrated Delivery Networks
September 26th 2018

Oncology Care Within Integrated Delivery Networks

The Unique Case of the VA Model
September 26th 2018

The Unique Case of the VA Model

Best-in-Class Healthcare Delivery Models
September 26th 2018

Best-in-Class Healthcare Delivery Models

Integrated Delivery Networks
September 26th 2018

Integrated Delivery Networks

The Role of Medium-Sized Employers
September 26th 2018

The Role of Medium-Sized Employers

Large Employers and Healthcare Consolidation
September 26th 2018

Large Employers and Healthcare Consolidation

The Impact of Consolidation on Healthcare Stakeholders
September 26th 2018

The Impact of Consolidation on Healthcare Stakeholders

Potential Benefits of Healthcare Consolidation
September 26th 2018

Potential Benefits of Healthcare Consolidation

Factors Behind Healthcare Consolidation
September 26th 2018

Factors Behind Healthcare Consolidation

The Advent of Managed Care
September 26th 2018

The Advent of Managed Care

History of Mergers and Acquisitions in the Healthcare Industry
September 26th 2018

History of Mergers and Acquisitions in the Healthcare Industry

Review Finds Mixed Results for APMs and New Care Delivery Models in Cancer
September 23rd 2018

Review Finds Mixed Results for APMs and New Care Delivery Models in Cancer

Laura Joszt, MA
With cancer costs rising and patients with cancer disproportionately facing financial toxicity, alternative payment and care delivery models are thought to help alleviate some of the cost burden. However, a review finds limited evidence available to evaluate the efficacy of alternative payment and care models in cancer care.
Podcast: This Week in Managed Care—Banning Gag Clauses and Other Health News
September 22nd 2018

Podcast: This Week in Managed Care—Banning Gag Clauses and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Bidens Celebrate Progress, Highlight Need for More at Biden Cancer Summit
September 22nd 2018

Bidens Celebrate Progress, Highlight Need for More at Biden Cancer Summit

Jaime Rosenberg
The flagship event of more than 450 Biden Cancer Community Summits convening throughout the day is focusing on sharing experiences, promoting new solutions, and bridging gaps in cancer care.
More Data Necessary to Determine Best Treatment Option in Basal Cell Carcinoma
September 21st 2018

More Data Necessary to Determine Best Treatment Option in Basal Cell Carcinoma

Samantha DiGrande
Although many different treatments exist for basal cell carcinoma (BCC), many methods have not been compared in head-to-head randomized trials. A review recently published in Annals of Internal Medicine looked to evaluate the comparative effectiveness and safety of treatments in adults with BCC.
This Week in Managed Care: September 21, 2018
September 21st 2018

This Week in Managed Care: September 21, 2018

This week, the top managed care news included the Senate overwhelmingly voting to ban pharmacist gag clauses; a study found the current vaccine pipeline for HIV, tuberculosis, and malaria may fall short; an expert noted a trend of healthcare cost data seeping into nonhealthcare companies’ earnings calls.
Amgen's AMG 420 Finds Early Success in Patients With Relapsing/Refractory Multiple Myeloma
September 20th 2018

Amgen's AMG 420 Finds Early Success in Patients With Relapsing/Refractory Multiple Myeloma

David Bai
Amgen’s pipeline drug AMG 420, a bispecific T-cell engager (BiTE) for the treatment of patients with relapsing/refractory multiple myeloma (RRMM), has found positive preliminary results in a phase 1 trial.
Dr Denalee O'Malley Highlights Gaps in Cancer Treatment Communication
September 19th 2018

Dr Denalee O'Malley Highlights Gaps in Cancer Treatment Communication

Assessing a patient’s understanding of his or her own illness is important as cancer treatments become more and more complex, said Denalee O’Malley, PhD, LSW, instructor, Department of Family Medicine and Community Health, Rutgers Robert Wood Johnson Medical School.
A Multidisciplinary Approach to Managing Complexities in Cancer Care
September 19th 2018

A Multidisciplinary Approach to Managing Complexities in Cancer Care

As September marks National Ovarian Cancer Awareness Month, we sat down with ovarian cancer survivor Marion Roth and Vaagn Andikyan, MD, gynecologic oncologist, Western Connecticut Health Network, to discuss Marion's cancer journey and the importance of a multidisciplinary care team in treating complexities in cancer care.
Prostate Cancer in Older Men Costs Medicare $1.2 Billion Over 3-Year Period
September 19th 2018

Prostate Cancer in Older Men Costs Medicare $1.2 Billion Over 3-Year Period

Jaime Rosenberg
With general consensus that those 70 years and older should not be routinely screened for prostate cancer, researchers argue that their study results identify an area for cutting low-value services to reduce healthcare spending.
Keytruda Earns Priority Review as Monotherapy in NSCLC
September 17th 2018

Keytruda Earns Priority Review as Monotherapy in NSCLC

Samantha DiGrande
Last week, the FDA granted priority review to a new supplemental Biologics License Application for pembrolizumab (Keytruda) as a monotherapy for first-line treatment of locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 without EGFR or ALK mutations.
Site Logo
September 17th 2018

Low-Dose Aspirin Won't Prolong Life in Healthy Older People, Study Announces

Mary Caffrey
The study by the National Institute on Aging produced a few surprises and was stopped early when aspirin showed no benefit.
NCCN Working Group Policy Recommendations Address Changing Paradigms in Cancer Care
September 16th 2018

NCCN Working Group Policy Recommendations Address Changing Paradigms in Cancer Care

Jaime Rosenberg
A National Comprehensive Cancer Network (NCCN) working group dedicated to analyzing current challenges under existing policy and treatment paradigms presented their findings and recommendations at an NCCN Policy Summit in Washington, DC.
<1
...
383940414243444546
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo